NeuroPace, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Joel D. Becker
- Full Time Employees
- 184
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 455 North Bernardo Avenue Mountain View CA United States of America 94043
- IPO Date
- Apr 22, 2021
- CIK
- 0001528287
- Website
- neuropace.com
- Similar Companies
- Business
- NeuroPace, Inc. develops and commercializes the RNS System, a brain-responsive neuromodulation platform that delivers personalized, real-time electrical stimulation to treat drug-resistant focal epilepsy by detecting and interrupting abnormal brain activity at its source; the system comprises an implantable RNS neurostimulator, cortical strip and depth leads, Patient Remote Monitor, physician tablet, patient data management system, and nSight Platform for ongoing monitoring and data analysis; it also offers implantable and non-implantable accessories sold primarily to hospital facilities for initial implants and replacements. Headquartered in Mountain View, California, and founded in 1997, the company operates in the United States within the medical device sector, targeting adults with drug-resistant epilepsy and expanding into idiopathic generalized epilepsy through clinical studies. Recent developments include third-quarter 2025 revenue of $27.4 million, up 30% year-over-year, with raised full-year 2025 guidance to $97-98 million and gross margins of 76-77%; a completed FDA pre-submission for the NAUTILUS study evaluating RNS therapy in idiopathic generalized epilepsy, on track for premarket approval supplement submission by year-end 2025; CMS reimbursement increases for 2026 under Physician Fee Schedule and Outpatient Prospective Payment System, boosting payments up to 47%; a new $75 million credit facility with MidCap Financial; appointment of Patrick F. Williams as CFO in June 2025; and planned highlights of AI-powered tools like SeizureID and long-term outcomes at the 2025 American Epilepsy Society meeting.
NPCE Receives FDA Approval for AI-Powered ECoG Assistant for Epilepsy
NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting
NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care
Is NPCE Stock a Buy in 2026 After DIXI Exit and Margin Lift?
NPCE Explains How NeuroPace's RNS System Makes Money
NeuroPace NPCE and the Next Wave of AI-Driven Epilepsy Care
NPCE Stock Gains on Q1 Earnings & Revenue Beat, 2026 Outlook Raised
NeuroPace, Inc. (NPCE) Q1 2026 Earnings Call Transcript
NeuroPace Q1 Earnings Call Highlights
NeuroPace, Inc. (NPCE) Reports Q1 Loss, Tops Revenue Estimates
NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance
NeuroPace (NPCE) Moves 6.3% Higher: Will This Strength Last?
NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026
NeuroPace (NASDAQ:NPCE) & Advanced Biomedical Technologies (OTCMKTS:ABMT) Head to Head Survey
NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference
Contrasting NeuroPace (NASDAQ:NPCE) & Integer (NYSE:ITGR)
NeuroPace (NPCE) Up 0.9% Since Last Earnings Report: Can It Continue?
Here's Why You Should Add NeuroPace Stock to Your Portfolio Now
Wall Street Analysts See a 41.29% Upside in NeuroPace (NPCE): Can the Stock Really Move This High?
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of “Moderate Buy” from Brokerages